Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection

CompletedOBSERVATIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Cytomegalovirus Infections
Trial Locations (15)

11030

Steven & Alexandra Cohen Children's Medical Center of New York (CCMC), Manhasset

14642

University of Rochester, Rochester

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

21287

Johns Hopkins Medical Institutions, Baltimore

28203

Carolinas Medical Center - Charlotte, Charlotte

33701

University of South Florida School of Medicine, St. Petersburg

35233

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

43205

Nationwide Childrens Hospital, Columbus

44109

MetroHealth Medical Center, Cleveland

63110

Washington University in St Louis School of Medicine, St Louis

71103

Louisiana State University Health Science Center - Shreveport, Shreveport

72202

University of Arkansas for Medical Sciences, Little Rock

02903

Rhode Island Hospital, Providence

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT01602614 - Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection | Biotech Hunter | Biotech Hunter